Drugs / Y-shape pegylated somatropin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04513171 | Dec 2018 → Jun 2023 | pituitary deficiency | Xiamen Amoytop Biotech Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Y-shape pegylated somatropin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04513171 ↗ |
| Known as | YPEG-rhGH | “of Y-shape branched PEGylated recombinant human growth hormone (YPEG-rhGH)” PMID 36034448 ↗ Aug 2022 |
| Modality | Protein / enzyme biologic | “Y-shape branched PEGylated recombinant human growth hormone (YPEG-rhGH)” PMID 36034448 ↗ Aug 2022 |
| Route | Subcutaneous | “subcutaneous injection” NCT04513171 ↗ |